OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Waxman on Selinexor in Multiple Myeloma Treatment

October 25th 2019

Adam J. Waxman, MD, MS, discusses the STORM trial and using selinexor to treat patients with multiple myeloma.

Dr. Koo on Next-Generation Imaging in Prostate Cancer

October 25th 2019

Phillip J. Koo, MD, discusses next-generation imaging tools in prostate cancer.

Dr. Benson on Sequencing Strategies with Cetuximab in CRC

October 25th 2019

Al B. Benson, MD, discusses the optimal sequencing of the EGFR inhibitor cetuximab for patients with RAS wild-type colorectal cancer.

Dr. Wierda on the ASCEND Trial and BTK Inhibitor-Based Therapies in CLL

October 25th 2019

William G. Wierda, MD, PhD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma

October 25th 2019

Jeffrey S. Weber, MD, PhD, discusses the future of checkpoint inhibitors in melanoma.

Dr. Ng on Immunotherapy in Micrometastatic High-Risk Soft Tissue Sarcoma

October 25th 2019

Vincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Dr. Bhatt on Finding a PD-L1 Pathway of Resistance in RCC

October 25th 2019

Rupal S. Bhatt, MD, PhD, discusses the potential identification of a pathway of resistance for PD-L1 in renal cell carcinoma.

Dr. Cho on Investigational BiTE Therapies in Multiple Myeloma

October 25th 2019

Hearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.

Dr. Kim on Clinical Trial Eligibility Criteria in Lung Cancer

October 25th 2019

Edward S. Kim, MD, discusses clinical trial eligibility criteria in lung cancer.

Dr. Bryce on Treatment Selection in Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Smith on Frontline Treatment Considerations in CLL

October 24th 2019

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Dr. Patel on Treatment Considerations in Advanced Squamous NSCLC

October 24th 2019

Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.

Dr. Babushok on Treatment Advances in Paroxysmal Nocturnal Hemoglobinuria

October 24th 2019

Daria V. Babushok, MD, PhD, discusses treatment advances in paroxysmal nocturnal hemoglobinuria.

Dr. Kasi on the Prognostic Value of ctDNA in CRC

October 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

Dr. Molena on Determining Surgical Resection Eligibility in NSCLC

October 24th 2019

Daniela Molena, MD, discusses factors that determine if a patient with non–small cell lung cancer is eligible for surgical resection.

Dr. de Wit on Rationale for Phase III CARD Trial in Metastatic CRPC

October 24th 2019

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Dr. Giri on the PROGRESS Registry for Genetic Testing in Prostate Cancer

October 24th 2019

Veda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.

Dr. Shah on the Trastuzumab Biosimilar in Gastric Cancer

October 24th 2019

Manish A. Shah, MD, discusses the use of trastuzumab biosimilars in gastric cancer.

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC

October 23rd 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

Dr. George on the Changing Treatment Landscape in Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses the changing treatment landscape in prostate cancer.